Xoma (XOMA -1.4%) says it's begun Phase 3 safety and efficacy studies of Gevokizumab, an...

|About: XOMA Corporation (XOMA)|By:, SA News Editor

Xoma (XOMA -1.4%) says it's begun Phase 3 safety and efficacy studies of Gevokizumab, an antibody used to treat diabetes and inflammatory disorders.